secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000010795-23-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD Q2 fiscal 2023 revenue $4.82B, adjusted EPS $2.86; raises guidance
---------------------------------------------------------------------

- Revenue $4.821B, up 1.5% reported (+4.1% currency-neutral); base revenue (ex-COVID) up 6.0% reported (+8.7% currency-neutral).
- GAAP diluted EPS $1.53; adjusted diluted EPS $2.86, up 2.9% reported (+11.2% currency-neutral).
- Company raises full-year base revenue and adjusted EPS guidance midpoints, enabling additional growth investments.
- FDA approval for BD Onclarity HPV assay with SurePath and ThinPrep; BD Vaginal Panel cleared for BD COR system; BD Prevue II system launched.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000001079523000038/0000010795-23-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000001079523000038/bdx-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000010795-23-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer